Literature DB >> 9926169

Time course of symptom resolution in patients with community-acquired pneumonia.

J P Metlay1, S J Atlas, L H Borowsky, D E Singer.   

Abstract

The majority of patients with community-acquired pneumonia are at low risk for short-term mortality or serious morbidity and are increasingly managed in the outpatient setting. Efforts to improve the quality of care for these patients will need to measure patient outcomes such as disease-specific symptom resolution. The aims of this study were to (1) develop a self-administered daily version of a symptom questionnaire for patients with pneumonia, (2) measure the reliability of this instrument, and (3) provide estimates for recovery rates based on symptom resolution in a cohort of low-risk patients with community-acquired pneumonia. This study was conducted as part of a prospective study of a new emergency department protocol for pneumonia at the Massachusetts General Hospital. Eligible study subjects included all adult patients with pneumonia presenting to the emergency department with a predicted low risk of short-term mortality. The main outcome measures were based on a new five item symptom questionnaire which rates the severity of cough, fatigue, dyspnea, myalgia, and fever. The questionnaires were self-administered on days 0-7, 14, 21 and 28 from the time of diagnosis of pneumonia. The symptom questions were also administered during patient interviews on days 0, 7, 14 and 28 in order to assess the questionnaire's reliability. Of the 166 eligible patients, 134 (81%) consented to participate in this study. The mean intra-class reliability coefficient of the symptom questionnaire was 0.75. The median times to resolution of individual symptoms ranged from 3 days for fever to 14 days for cough and fatigue. Thirty-five percent of patients had at least one symptom still present at the end of the 28-day study period. We found that a daily self-report questionnaire is a reliable measure of symptom resolution for patients with pneumonia. Full resolution of symptoms takes more than 28 days for a significant proportion of patients with pneumonia.

Entities:  

Mesh:

Year:  1998        PMID: 9926169     DOI: 10.1016/s0954-6111(98)90408-5

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  11 in total

1.  Development and validation of a short questionnaire in community acquired pneumonia.

Authors:  R El Moussaoui; B C Opmeer; P M M Bossuyt; P Speelman; C A J M de Borgie; J M Prins
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

2.  Healthcare reconsultation in working-age adults following hospitalisation for community-acquired pneumonia.

Authors:  Priya Daniel; Thomas Bewick; Tricia M McKeever; Mark Roberts; Deborah Ashton; Daniel Smith; Lenny Latip; Wei Shen Lim
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

3.  Determining the duration of therapy for patients with community-acquired pneumonia.

Authors:  Nikole M Scalera; Thomas M File
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

4.  Community-acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older.

Authors:  Kathleen W Wyrwich; Holly Yu; Reiko Sato; David Strutton; John H Powers
Journal:  Patient       Date:  2013       Impact factor: 3.883

Review 5.  [Assessment, triage, and follow-up of a patient with: acute CAP COPD].

Authors:  K Faure
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

6.  Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis.

Authors:  George Dimopoulos; Dimitrios K Matthaiou; Drosos E Karageorgopoulos; Alexandros P Grammatikos; Zoe Athanassa; Matthew E Falagas
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.

Authors:  Thomas M File; Elizabeth Alexander; Lisa Goldberg; Anita F Das; Christian Sandrock; Susanne Paukner; Gregory J Moran
Journal:  BMC Pulm Med       Date:  2021-05-08       Impact factor: 3.317

8.  Patient-reported outcome measures in community-acquired pneumonia: a systematic review of application and content validity.

Authors:  Melanie Lloyd; Emily Callander; Amalia Karahalios; Lucy Desmond; Harin Karunajeewa
Journal:  BMJ Open Respir Res       Date:  2019-06-02

9.  Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire.

Authors:  Kathleen W Wyrwich; Holly Yu; Reiko Sato; John H Powers
Journal:  Patient Relat Outcome Meas       Date:  2015-07-30

Review 10.  Community-acquired pneumonia.

Authors:  Thomas M File
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.